new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)





Similar
Filing Names

Shire Human Genetic Therapies Inc
Shire Human Genetic Therapies Inc A Delaware Corporation
  

Shire Human Genetic Therapies Inc patents

Recent patent applications related to Shire Human Genetic Therapies Inc. Shire Human Genetic Therapies Inc is listed as an Agent/Assignee. Note: Shire Human Genetic Therapies Inc may have other listings under different names/spellings. We're not affiliated with Shire Human Genetic Therapies Inc, we're just tracking patents.

ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "S" | Shire Human Genetic Therapies Inc-related inventors




Date Shire Human Genetic Therapies Inc patents (updated weekly) - BOOKMARK this page
03/16/17Mrna therapy for phenylketonuria
03/16/17Purification of iduronate-2-sulfatase
02/16/17Methods and compositions for cns delivery of heparan n-sulfatase
02/16/17Cns delivery of therapeutic agents
12/22/16Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
12/15/16Method of characterizing lysosomal enzymes
11/10/16Mrna therapy for pompe disease
10/06/16Liver specific delivery of messenger rna
10/06/16Anti-ccl2 antibodies for treatment of scleroderma
08/18/16Mitochondrial targeting and therapeutic use thereof
06/30/16Treatment of alpha-galactosidase a deficiency
06/30/16Mrna therapeutic compositions and use to treat diseases and disorders
06/09/16Methods and compositions for cns delivery of iduronate-2-sulfatase
06/09/16Messenger rna therapy for treatment of articular disease
06/02/16Synergistic enhancement of the delivery of nucleic acids via blended formulations
06/02/16Peptide linkers for polypeptide compositions and methods for using same
05/12/16C1 inhibitor fusion proteins and uses thereof
05/05/16Messenger rna based viral production
04/21/16Cftr mrna compositions and related methods and uses
04/14/16Mrna for use in treatment of human genetic diseases
03/24/16Anti-ccl2 and anti-loxl2 combination therapy for treatment of scleroderma
03/24/16Follistatin in treating duchenne muscular dystrophy
02/25/16Lipoprotein lipase for treatment of hypertriglyceridemic-related conditions including acute pancreatitis
02/25/16Cells for producing recombinant iduronate-2-sulfatase
02/11/16Encapsulation of messenger rna
02/11/16Methods for purification of messenger rna
02/04/16Methods of treating b2-bradykinin receptor mediated angioedema
02/04/16Ribonucleic acids with 4'-thio-modified nucleotides and related methods
02/04/16Methods and compositions for delivering mrna coded antibodies
02/04/16Quantitative assessment for cap efficiency of messenger rna
01/07/16Quantitative assessment for cap efficiency of messenger rna
12/31/15Stereochemically enriched compositions for delivery of nucleic acids
12/31/15Methods for purification of messenger rna
12/24/15Compositions and methods for mrna delivery
12/24/15Placenta growth factor in treating duchenne muscular dystrophy
12/17/15Anti-flt-1 antibodies in treating duchenne muscular dystrophy
12/10/15Methods for purification of arysulfatase a
11/26/15Competition based-detection assays
11/19/15Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
11/05/15Purification of iduronate-2-sulfatase
10/29/15Subcutaneous administration of alpha-galactosidase a
10/08/15Stabilized compositions of proteins having a free thiol moiety
09/24/15Nuclease resistant polynucleotides and uses thereof
09/17/15Assays for detection of glycosaminoglycans
06/18/15Ionizable cationic lipids
06/11/15Pulmonary delivery of mrna to non-lung target cells
06/11/15Anti-ccl2 antibodies for treatment of scleroderma
05/21/15Lipid formulations for delivery of messenger rna
04/23/15Cns delivery of mrna and uses thereof
04/23/15Mrna therapy for phenylketonuria
04/23/15Mrna therapy for argininosuccinate synthetase deficiency
03/26/15Subcutaneous administration of iduronate- 2-sulfatase
03/26/15Lipid-derived neutral nanoparticles
03/12/15Compositions and methods for treating type iii gaucher disease
02/05/15Cftr mrna compositions and related methods and uses
01/29/15Crystal structure of human alpha-n-acetylglucosaminidase
01/15/15Assays for detection of glycosaminoglycans
01/08/15Methods for preparation of culture media
01/01/15Mrna for use in treatment of human genetic diseases
12/25/14Stable formulations for cns delivery of arylsulfatase a
11/27/14Optimized messenger rna
10/09/14Enzymatic activity based-detection
10/02/14Method of characterizing lysosomal enzymes
09/25/14Cleavable lipids
09/18/14Methods and compositions for cns delivery of iduronate-2-sulfatase
Patent Packs
08/28/14Compositions and methods for treating gaucher disease
08/07/14Stabilized compositions of proteins having a free thiol moiety
08/07/14Competition-based detection assays
07/24/14Methods for purification of arylsulfatase a
07/24/14Lipid nanoparticle compositions and methods for mrna delivery
07/03/14Peptide linkers for polypeptide compositions and methods for using same
05/15/14Mitochondrial targeting and therapeutic use thereof
02/27/14Assays for antibodies which bind to therapeutic agents
02/06/14Subcutaneous administration of alpha-galactosidase a
12/19/13Assays and kits to determine galactocerebrosidase activity on solid support
08/01/13Mannose receptor c type 1 (mrc1) codon optimized cell line and uses thereof
08/01/13Liver specific delivery of messenger rna
07/25/13Assays for detection of glycosaminoglycans
07/04/13Gene therapy for sulfatase deficiency
06/27/13Systems and methods for managing treatment of an orphan disease
Patent Packs
05/16/13Biomarkers for sanfilippo syndrome and uses thereof
01/31/13Diagnosis and treatment of multiple sulfatase deficiency and other sulfatase deficiencies
01/26/12Crystal structure of human alpha-n-acetylglucosaminidase
01/19/12Methods and compositions for cns delivery of heparan n-sulfatase
01/12/12Methods and compositions for cns delivery of arylsulfatase a
01/05/12Cns delivery of therapeutic agents
12/29/11Methods and compositions for cns delivery of iduronate-2-sulfatase
12/29/11Methods and compositions for cns delivery of b-galactocerebrosidase
12/29/11Treatment of sanfilippo syndrome type b
11/18/10Subcutaneous administration of alpha-galactosidase a
06/10/10In vivo production and delivery of erythropoietin or insulinotropin for gene therapy
06/11/09Optimized messenger rna







ARCHIVE: New 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Shire Human Genetic Therapies Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Shire Human Genetic Therapies Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###




';